ARCHIVES

Nexavar Phase III Trial Fails To Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Low-Dose Tamoxifen May Be Effective In Treating Breast Cancer, Study Finds

April 25, 2003

Georgetown Sponsors Oncology Agent Development Meeting

February 21, 2003

Senate Passes Non-Binding Resolution To Double NIH Budget Over Five Years

May 23, 1997

FDA Moves To Revoke Avastin’s Breast Cancer Accelerated Approval, Genentech Vows To Fight

December 17, 2010

Rauscher Tabs Oak Ridge Immunologists To Head Basic Research At Frederick

August 30, 1974

FDA To Expand Disclosure For Advisory Committee Members

April 23, 2010